Clarivate exceeded sales and earnings projections for Q4, with revenue down 7% but better than expected. The company is considering selling its life sciences and healthcare division. Stock price surged 31.4% on Tuesday following the positive earnings report. Clarivate aims for 10% free cash flow growth this year and anticipates 2-3% growth in annual contract value. The plan to sell the life sciences unit is seen as a positive move to reduce debt and expand in other areas. Investors are reacting favorably to the news, but analysts recommend other stocks for potential high returns.

Read more at Nasdaq: Why Clarivate Stock Is Skyrocketing Today